What is Mavyret, and what is it used for?
Mavyret is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).
Mavyret is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.
What are the side effects of Mavyret?
Risk of hepatitis B virus reactivation in patients coinfected with HCV and HBV
Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with Mavyret. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.
Common side effects of Mavyret include:
What is the dosage of Mavyret?
Mavyret is a fixed-dose combination product containing glecaprevir 100 mg and pibrentasvir 40 mg in each tablet.
The recommended oral dosage of Mavyret is 3 tablets taken at the same time once daily with food (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).
Liver Or Kidney Transplant Recipients
Mavyret is recommended for 12 weeks in adult and pediatric patients 12 years and older or weighing at least 45 kg who are liver or kidney transplant recipients. A 16-week treatment duration is recommended in genotype 1-infected patients who are NS5A inhibitor-experienced without prior treatment with an NS3/4A protease inhibitor or in genotype 3-infected patients who are PRS treatment-experienced.
Mavyret is not recommended in patients with moderate hepatic impairment (Child-Pugh B) and is contraindicated in patients with severe hepatic impairment (Child-Pugh C).
Latest Infectious Disease News
- Antibiotic-Resistant Pneumonia Is Killing Children
- H5N6 Bird Flu Infection Hits China
- New Superbug Spread Could Threaten Humans
- Global Warming Means Spread of Malaria, Dengue
- Listeria Outbreak Linked to Precooked Chicken
- Want More News? Sign Up for MedicineNet Newsletters!
Daily Health News
- H5N6 Bird Flu Infection in China
- COVID Vaccine Misinformation
- Antibiotic-Resistant Pneumonia
- Mask Mandate Returns to L.A.
- Fermented Foods Help Microbiome
- More Health News »
Trending on MedicineNet
- Guillain-Barre Syndrome
- What Triggers Shingles?
- Normal Blood Sugar Levels
- Identify Tick Bites
- Why Is Autism Increasing?
What drugs interact with Mavyret?
Mechanisms For The Potential Effect Of Mavyret On Other Drugs
Glecaprevir and pibrentasvir are inhibitors of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and organic anion transporting polypeptide (OATP) 1B1/3. Coadministration with Mavyret may increase plasma concentration of drugs that are substrates of P-gp, BCRP, OATP1B1 or OATP1B3. Glecaprevir and pibrentasvir are weak inhibitors of cytochrome P450 (CYP) 3A, CYP1A2, and uridine glucuronosyltransferase (UGT) 1A1.
Fluctuations in INR values may occur in patients receiving warfarin concomitant with HCV treatment, including treatment with Mavyret. If Mavyret is coadministered with warfarin, close monitoring of INR values is recommended during treatment and post-treatment follow-up.
Mechanisms for The Potential Effect Of Other Drugs On Mavyret
Glecaprevir and pibrentasvir are substrates of P-gp and/or BCRP. Glecaprevir is a substrate of OATP1B1/3. Coadministration of Mavyret with drugs that inhibit hepatic P-gp, BCRP, or OATP1B1/3 may increase the plasma concentrations of glecaprevir and/or pibrentasvir.
Coadministration of Mavyret with drugs that induce P-gp/CYP3A may decrease glecaprevir and pibrentasvir plasma concentrations.
Carbamazepine, phenytoin, efavirenz, and St. John’s wort may significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect of Mavyret. The use of these agents with Mavyret is not recommended.
Table 5: Potentially Significant Drug Interactions Identified in Drug Interaction StudiesConcomitant Drug Class: Drug NameEffect on ConcentrationClinical CommentsAntiarrhythmics:Digoxin↑ digoxinMeasure serum digoxin concentrations before initiating Mavyret. Reduce digoxin concentrations by decreasing the dose by approximately 50% or by modifying the dosing frequency and continue monitoring.Anticoagulants:Dabigatran etexilate↑dabigatranIf Mavyret and dabigatran etexilate are coadministered, refer to the dabigatran etexilate prescribing information for dabigatran etexilate dose modifications in combination with P-gp inhibitors in the setting of renal impairment.Anticonvulsants:Carbamazepine↓ glecaprevir
↓pibrentasvirCoadministration may lead to reduced therapeutic effect of Mavyret and is not recommended.Antimycobacterials:Rifampin↓ glecaprevir
↓ pibrentasvirCoadministration is contraindicated because of potential loss of therapeutic effect .Ethinyl Estradiol-Containing Products:Ethinyl estradiol-containing medications such as combined oral contraceptives↔ glecaprevir
↔ pibrentasvirCoadministration of Mavyret may increase the risk of ALT elevations and is not recommended.Herbal Products:St. John’s wort (hypericum perforatum)↓ glecaprevir
↓ pibrentasvirCoadministration may lead to reduced therapeutic effect of Mavyret and is not recommended.HIV-Antiviral Agents:Atazanavir↑glecaprevir
↑ pibrentasvirCoadministration is contraindicated due to increased risk of ALT elevations.Darunavir Lopinavir Ritonavir↑ glecaprevir
↑ pibrentasvirCoadministration is not recommended.Efavirenz↓ glecaprevir
↓ pibrentasvirCoadministration may lead to reduced therapeutic effect of Mavyret and is not recommended.HMG-CoA Reductase Inhibitors:Atorvastatin Lovastatin Simvastatin↑ atorvastatin
↑ simvastatinCoadministration may increase the concentration of atorvastatin, lovastatin, and simvastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Coadministration with these statins is not recommended.Pravastatin↑ pravastatinCoadministration may increase the concentration of pravastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Reduce pravastatin dose by 50% when coadministered with Mavyret.Rosuvastatin↑ rosuvastatinCoadministration may significantly increase the concentration of rosuvastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Rosuvastatin may be administered with Mavyret at a dose that does not exceed 10 mg.Fluvastatin Pitavastatin↑ fluvastatin
↑ pitavastatinCoadministration may increase the concentrations of fluvastatin and pitavastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Use the lowest approved dose of fluvastatin or pitavastatin. If higher doses are needed, use the lowest necessary statin dose based on a risk/benefit assessment.Immunosuppressants:Cyclosporine↑ glecaprevir
↑pibrentasvirMavyret is not recommended for use in patients requiring stable cyclosporine doses > 100 mg per day.↑= increase; ↓= decrease; ↔ = no effect
Drugs With No Observed Clinically Significant Interactions With Mavyret
No dose adjustment is required when Mavyret is coadministered with the following medications:
- norethindrone or other progestin-only contraceptives,
- tenofovir alafenamide,
- tenofovir disoproxil fumarate,
- tolbutamide, and
Hepatitis C virus causes an infection of the ______________.
Is Mavyret safe to take while pregnant or breastfeeding?
No adequate human data are available to establish whether or not Mavyret poses a risk to pregnancy outcomes. In animal reproduction studies, no adverse developmental effects were observed when the components of Mavyret were administered separately during organogenesis at exposures up to 53 times (rats; glecaprevir) or 51 and 1.5 times (mice and rabbits, respectively; pibrentasvir) the human exposures at the recommended dose of Mavyret.
No definitive conclusions regarding potential developmental effects of glecaprevir could be made in rabbits, since the highest achieved glecaprevir exposure in this species was only 7% (0.07 times) of the human exposure at the recommended dose.
There were no effects with either compound in rodent pre/post-natal developmental studies in which maternal systemic exposures (AUC) to glecaprevir and pibrentasvir were approximately 47 and 74 times, respectively, the exposure in humans at the recommended dose.
It is not known whether the components of Mavyret are excreted in human breast milk, affect human milk production, or have effects on the breastfed infant. When administered to lactating rodents, the components of Mavyret were present in milk, without effect on growth and development observed in the nursing pups.
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Mavyret and any potential adverse effects on the breastfed child from Mavyret or from the underlying maternal condition.